Eiman Aleem, Ph.D., M.Sc.

Associate Professor; Research Track Research Scientist


Dr. Aleem joined the Institute of Molecular Medicine (IMM) at Phoenix Children’s hospital in early 2013. As part of a precision medicine approach to identify novel therapeutic targets and improve treatment options for pediatric cancers, Dr. Aleem’s translational research focuses on (1) understanding the association between cancer genotype and phenotype, i.e. how the genomic/transcriptomic alterations in cancer cells lead to cancer-specific biological effects, such as uncontrolled cell proliferation, drug resistance and escape from apoptosis, (2) Identification of drugs targeting cancer stem cells and studying the mechanisms of action of drugs currently in clinical trials, as well as (3) studying the effect of the tumor microenvironment on the response of cancer cells to therapy. Dr. Aleem applies a variety of innovative technologies in her research including next-generation sequencing, functional proteomics, kinome profiling, in vitro 3D cell culture models and in vivo mice models. Current projects in the lab include: (1) Integrating Functional Proteomics To Identify Novel Therapeutic Targets in AML, (2) Development Of An In Vitro Microenvironment Assay For Accurate Drug Response Testing, (3) Targeting Novel Mechanisms of Cell Death in Pediatric Cancer. Dr. Aleem is also a co-investigator on two PCH collaborative projects with the industry: (4) the validation protocol of the Complete Cancer Care Diagnostics (C3Dx) clinical trial with Perian Dx, and (5) New Biomarkers Of Efficacy: Clinical Trial With Carfilzomib, with Onyx Pharmaceuticals. Dr. Aleem received her Ph. D. in molecular biology from Heidelberg University and the German Cancer Research Center (DKFZ), Germany working on the insulin and insulin-like growth factor-1 receptor (IGF-1R) signaling in liver cancer. She received a postdoctoral fellowship from the NIH at NCI-Frederick, to study the regulation of the mammalian cell cycle using knockout mouse models. Dr. Aleem was a Professor at Alexandria University, Egypt and a Senior Scientist and Associate Professor at Karolinska Institutet, Stockholm, Sweden, where she continued her work on the IGF-1R functions in stem cells and its therapeutic targeting in cancer.



Child Health


Ph.D.: Molecular Biology


  • Aleem, E. and Arceci, R.J. (2015). Targeting Cell Cycle Regulators in Hematologic Malignancies. Frontiers of Cell and Developmental Biology 3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Review.
  • Waraky A, Akopyan K, Parrow V, Stromberg T, Axelson M, Abrahmsen, L, Lindqvist A, Larsson O and Aleem E (2014): Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism. Oncotarget, Sep 30;5(18):8379-92
  • Soffar A, Storch K, Aleem E, Cordes N (2013). CDK2 knockdown enhances head and neck cancer cell radiosensitivity. International Journal of Radiation Biology 2013 Apr 16. [Epub ahead of print]
  • Mansour A, Daba, A, Baddour N, Elsaadani M, Aleem, E (2012). Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen. Journal of Cancer Research and Clinical Oncology, 138(9):1579-96
  • Aleem E, Nehrbass D, Klimek F, Bannasch P and Mayer D (2011). Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicologic Pathology, 39(3): 524-543.
  • Padmakumar VC, Aleem E, Berthet C, Hilton MB and Kaldis P (2009). Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Molecular and Cellular Biology, 29(10): 2582-2593
  • Li WQ, Jiang Q, Aleem E, Kaldis P, Khaled AR and Durum SK (2006). IL-7 promotes T cell proliferation through destabilization of p27Kip1. Journal of Experimental Medicine, 203 (3): 573-582
  • Robinson-White A, Leitner W, Aleem E, Kaldis P and Stratakis C (2006). PRKAR1A- inactivation leads to increased proliferation and decreased apoptosis in human B-lymphocytes. Cancer Research, 66 (21): 10603-10612
  • Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL and Megyesi J (2006). Dependence of Cisplatin-Induced Cell Death In Vitro and In vivo on cyclin-dependent kinase 2. Journal of the American Society of Nephrology 17: 2434-2442
  • Aleem E, Kiyokawa H and Kaldis P (2005). Cdc2/cyclinE regulates the G1/S phase transition. Nature Cell Biology: 7(8): 831-836
  • Adelson PD, Srinivas R, Chang YF, Bell MJ, Kochanek PM. Cerebrovascular response in children following severe traumatic brain injury. Child

Share this page: